Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of pre-percutaneous coronary intervention ticagrelor administration on coronary reperfusion and short-term prognosis in patients with acute myocardial infarction

Tan Xue¹, Hongyan Zhang¹, Jiahui Wu², Chunfeng Li¹

¹Department of Cardiology, the Second Affiliated Hospital of Qiqihar Medical College, Qiqihar Medical University, Lianda Lijing Community, Xiyuan Community, Jianhua District, Qiqihar City, China; ²Department of Environment and Occupational Health, School of Public Health, Qiqihar Medical University, Lianda Lijing Community, Xiyuan Community, Jianhua District, Qiqihar City, China.

For correspondence:- Chunfeng Li Email: Lichunf222@outlook.com

Accepted: 23 May 2023 Published: 30 June 2023

Citation: Xue T, Zhang H, Wu J, Li C. Effect of pre-percutaneous coronary intervention ticagrelor administration on coronary reperfusion and short-term prognosis in patients with acute myocardial infarction. Trop J Pharm Res 2023; 22(6):1327-1333 doi: 10.4314/tjpr.v22i6.24

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of ticagrelor administration prior to percutaneous coronary intervention (PCI) on coronary reperfusion and short-term prognosis in patients with acute myocardial infarction.

Methods: A total of 200 patients treated for acute myocardial infarction in The Second Affiliated Hospital of Qiqihar Medical College between May 2021 and October 2022 were assigned to receive either clopidogrel (control group) or ticagrelor (Ticagrelor group) before PCI, in a 1:1 ratio, with 100 patients in each group. Clinical indices, serum C-reactive protein (CRP), inhibition of platelet aggregation (IPA), lipid indices, coronary reperfusion, and short-term prognosis of the patients were analyzed to investigate the effectiveness of the pre-intervention.

Results: Patients receiving ticagrelor exhibited significantly lower levels of maximum platelet aggregation rate (MAR), P2Y12 reaction units (PRU), and left ventricular end-diastolic diameter (LVDD) and higher left ventricular ejection fraction (LVEF) than those given clopidogrel (p < 0.01). Also. patients administered pre-interventional ticagrelor administration exhibited significantly lower serum concentrations of total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) than those who received clopidogrel (p < 0.01), suggesting a better overall blood lipid profile for the former. Pre-PCI ticagrelor administration significantly mitigated inflammatory reactions more than clopidogrel, as evidenced by the reductions in serum CRP, cTnI, and CK-MB levels (p < 0.01). It further resulted in a lower risk of abnormal platelet aggregation than pre-interventional clopidogrel (p < 0.01).

Conclusion: Pre-interventional ticagrelor administration after the onset of acute myocardial infarction produces significant improvement in clinical indices and platelet indices, normalized blood lipid profiles, shortens coronary reperfusion, and enhances short-term prognosis of patients. Future randomized controlled trials with larger sample sizes and the use of more centers are required to validate the current results.

Keywords: Acute myocardial infarction, Ticagrelor, Coronary artery reperfusion, Short-term prognosis